KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC

Opinion
Video

Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Hope Rugo, MD, presenting slides
Related Content